vs
Side-by-side financial comparison of Dominari Holdings Inc. (DOMH) and GYRE THERAPEUTICS, INC. (GYRE). Click either name above to swap in a different company.
GYRE THERAPEUTICS, INC. is the larger business by last-quarter revenue ($37.2M vs $30.1M, roughly 1.2× Dominari Holdings Inc.). GYRE THERAPEUTICS, INC. runs the higher net margin — -3.7% vs -438.1%, a 434.4% gap on every dollar of revenue. On growth, Dominari Holdings Inc. posted the faster year-over-year revenue change (220.4% vs 33.4%). Over the past eight quarters, Dominari Holdings Inc.'s revenue compounded faster (369.1% CAGR vs 17.0%).
GYRE Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing novel targeted therapies for hard-to-treat hematologic malignancies and solid tumors. It focuses on precision oncology to address unmet patient needs, with operations primarily based in North America.
DOMH vs GYRE — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $30.1M | $37.2M |
| Net Profit | $-131.8M | $-1.4M |
| Gross Margin | — | 95.3% |
| Operating Margin | -8.9% | 0.3% |
| Net Margin | -438.1% | -3.7% |
| Revenue YoY | 220.4% | 33.4% |
| Net Profit YoY | -12426.2% | -340.1% |
| EPS (diluted) | $-6.94 | $-0.01 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $30.1M | $37.2M | ||
| Q3 25 | $50.8M | $30.6M | ||
| Q2 25 | $34.1M | $26.8M | ||
| Q1 25 | $8.1M | $22.1M | ||
| Q4 24 | $9.4M | $27.9M | ||
| Q3 24 | $4.0M | $25.5M | ||
| Q2 24 | $6.2M | $25.2M | ||
| Q1 24 | $1.4M | $27.2M |
| Q4 25 | $-131.8M | $-1.4M | ||
| Q3 25 | $125.2M | $5.9M | ||
| Q2 25 | $16.6M | $1.6M | ||
| Q1 25 | $-32.5M | $3.7M | ||
| Q4 24 | $1.1M | $569.0K | ||
| Q3 24 | $-4.2M | $2.9M | ||
| Q2 24 | $-6.1M | $4.5M | ||
| Q1 24 | $-5.4M | $9.9M |
| Q4 25 | — | 95.3% | ||
| Q3 25 | — | 94.7% | ||
| Q2 25 | — | 95.7% | ||
| Q1 25 | — | 95.9% | ||
| Q4 24 | — | 95.8% | ||
| Q3 24 | — | 96.2% | ||
| Q2 24 | — | 96.9% | ||
| Q1 24 | — | 96.4% |
| Q4 25 | -8.9% | 0.3% | ||
| Q3 25 | -3.1% | 22.7% | ||
| Q2 25 | -57.0% | 8.1% | ||
| Q1 25 | -394.6% | 10.3% | ||
| Q4 24 | 0.4% | 2.4% | ||
| Q3 24 | -79.1% | 16.6% | ||
| Q2 24 | -44.3% | 12.7% | ||
| Q1 24 | -205.2% | 29.7% |
| Q4 25 | -438.1% | -3.7% | ||
| Q3 25 | 246.4% | 19.4% | ||
| Q2 25 | 48.7% | 5.9% | ||
| Q1 25 | -400.5% | 16.9% | ||
| Q4 24 | 11.4% | 2.0% | ||
| Q3 24 | -104.2% | 11.2% | ||
| Q2 24 | -99.1% | 18.0% | ||
| Q1 24 | -398.0% | 36.6% |
| Q4 25 | $-6.94 | $-0.01 | ||
| Q3 25 | $7.27 | $0.03 | ||
| Q2 25 | $1.12 | $0.00 | ||
| Q1 25 | $-3.02 | $0.00 | ||
| Q4 24 | $0.21 | $0.00 | ||
| Q3 24 | $-0.67 | $0.01 | ||
| Q2 24 | $-1.01 | $0.01 | ||
| Q1 24 | $-0.91 | $0.03 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $80.5M | $52.4M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $69.4M | $106.0M |
| Total Assets | $112.9M | $166.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $80.5M | $52.4M | ||
| Q3 25 | $176.2M | $60.0M | ||
| Q2 25 | $28.2M | $54.4M | ||
| Q1 25 | $18.9M | $29.9M | ||
| Q4 24 | $8.2M | $26.7M | ||
| Q3 24 | $7.2M | $25.1M | ||
| Q2 24 | $12.1M | $25.1M | ||
| Q1 24 | $7.1M | $37.4M |
| Q4 25 | $69.4M | $106.0M | ||
| Q3 25 | $210.2M | $101.9M | ||
| Q2 25 | $88.6M | $92.0M | ||
| Q1 25 | $42.4M | $68.1M | ||
| Q4 24 | $39.9M | $63.3M | ||
| Q3 24 | $38.3M | $63.2M | ||
| Q2 24 | $42.4M | $60.4M | ||
| Q1 24 | $47.7M | $56.6M |
| Q4 25 | $112.9M | $166.1M | ||
| Q3 25 | $223.4M | $159.4M | ||
| Q2 25 | $109.3M | $152.6M | ||
| Q1 25 | $52.3M | $129.8M | ||
| Q4 24 | $47.1M | $125.4M | ||
| Q3 24 | $43.4M | $125.2M | ||
| Q2 24 | $49.1M | $120.9M | ||
| Q1 24 | $52.2M | $122.0M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $22.7M | $-5.6M |
| Free Cash FlowOCF − Capex | — | $-5.8M |
| FCF MarginFCF / Revenue | — | -15.5% |
| Capex IntensityCapex / Revenue | — | 0.4% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-180.0K |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $22.7M | $-5.6M | ||
| Q3 25 | $-4.9M | $4.7M | ||
| Q2 25 | $-353.0K | $2.1M | ||
| Q1 25 | $1.2M | $-129.0K | ||
| Q4 24 | $-16.7M | $-2.8M | ||
| Q3 24 | $-4.7M | $1.7M | ||
| Q2 24 | $1.4M | $-5.5M | ||
| Q1 24 | $-8.6M | $2.9M |
| Q4 25 | — | $-5.8M | ||
| Q3 25 | — | $4.0M | ||
| Q2 25 | — | $1.8M | ||
| Q1 25 | — | $-251.0K | ||
| Q4 24 | — | $-2.8M | ||
| Q3 24 | — | $1.0M | ||
| Q2 24 | — | $-6.9M | ||
| Q1 24 | — | $2.7M |
| Q4 25 | — | -15.5% | ||
| Q3 25 | — | 13.1% | ||
| Q2 25 | — | 6.8% | ||
| Q1 25 | — | -1.1% | ||
| Q4 24 | — | -10.1% | ||
| Q3 24 | — | 4.1% | ||
| Q2 24 | — | -27.5% | ||
| Q1 24 | — | 9.8% |
| Q4 25 | — | 0.4% | ||
| Q3 25 | — | 2.2% | ||
| Q2 25 | — | 1.0% | ||
| Q1 25 | — | 0.6% | ||
| Q4 24 | — | 0.2% | ||
| Q3 24 | — | 2.7% | ||
| Q2 24 | — | 5.8% | ||
| Q1 24 | — | 0.9% |
| Q4 25 | — | — | ||
| Q3 25 | -0.04× | 0.79× | ||
| Q2 25 | -0.02× | 1.32× | ||
| Q1 25 | — | -0.03× | ||
| Q4 24 | -15.65× | -4.85× | ||
| Q3 24 | — | 0.60× | ||
| Q2 24 | — | -1.21× | ||
| Q1 24 | — | 0.29× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
DOMH
| Chief Operating Decision Maker | $30.1M | 100% |
| Commissions | $458.0K | 2% |
GYRE
Segment breakdown not available.
